Switch theme
Sign up to access all valuation multiples
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lipum has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$5.6M.
In the most recent fiscal year, Lipum achieved revenue of n/a and an EBITDA of -$5.7M.
Lipum expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lipum valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$5.6M | XXX | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$5.6M | XXX | -$5.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$5.6M | XXX | -$5.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lipum's stock price is SEK 15 (or $2).
Lipum has current market cap of SEK 319M (or $32.9M), and EV of SEK 324M (or $33.5M).
See Lipum trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33.5M | $32.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lipum has market cap of $32.9M and EV of $33.5M.
Lipum's trades at n/a EV/Revenue multiple, and -5.9x EV/EBITDA.
Equity research analysts estimate Lipum's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lipum has a P/E ratio of -5.9x.
See valuation multiples for Lipum and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.9M | XXX | $32.9M | XXX | XXX | XXX |
| EV (current) | $33.5M | XXX | $33.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.0x | XXX | -5.9x | XXX | XXX | XXX |
| EV/EBIT | -6.0x | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.9x | XXX | -5.8x | XXX | XXX | XXX |
| EV/FCF | -4.7x | XXX | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLipum's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Lipum's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lipum's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lipum and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lipum acquired XXX companies to date.
Last acquisition by Lipum was XXXXXXXX, XXXXX XXXXX XXXXXX . Lipum acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Lipum headquartered? | Lipum is headquartered in Sweden. |
| How many employees does Lipum have? | As of today, Lipum has 5 employees. |
| Is Lipum publicy listed? | Yes, Lipum is a public company listed on STO. |
| What is the stock symbol of Lipum? | Lipum trades under LIPUM ticker. |
| When did Lipum go public? | Lipum went public in 2021. |
| Who are competitors of Lipum? | Similar companies to Lipum include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lipum? | Lipum's current market cap is $32.9M |
| Is Lipum profitable? | Yes, Lipum is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lipum? | Lipum's last 12 months EBITDA is -$5.6M. |
| What is the current EV/EBITDA multiple of Lipum? | Current EBITDA multiple of Lipum is -6.0x. |
| What is the current FCF of Lipum? | Lipum's last 12 months FCF is -$7.1M. |
| What is the current EV/FCF multiple of Lipum? | Current FCF multiple of Lipum is -4.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
